Oxford Immunotec said that it expects the report to further the trend toward interferon-gamma release assay adoption for healthcare personnel screening.
A Roche executive said he expects essentially all the firm's US troponin customers will convert to the high-sensitivity assay over the next two to three years.
The firm is working with a new center in Dakar, Senegal, that will deploy new tests based on the platform to support early detection of tropical diseases.
Flu test sales were the second-highest for a quarter in the firm's history but were still $17.4 million lower than the year-ago quarter due to a much less intense flu season.
The firm said it has multiple point-of-care tests available in Brazil and anticipates soon fulfilling an order for its dengue, chikungunya, and Zika tests.
Researchers reported that elevated high-sensitivity troponin I is strongly associated with increased risk of cardiovascular disease in some populations.
The NEO Iris instrument uses the company's Capture solid phase technology for antibody screening and identification, and can run up to 60 tests and screens per hour.
In the quarter the firm acquired food and beverage testing firm Invisible Sentinel and partnered with Baxter International to develop acute kidney injury biomarkers.
ArcDia will provide Xinhua its biochemical assay components and R&D services in order to localize the Finnish firm's MariPOC testing platform in China.
